PMID- 34830221
OWN - NLM
STAT- MEDLINE
DCOM- 20211220
LR  - 20211220
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 22
DP  - 2021 Nov 15
TI  - Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.
LID - 10.3390/ijms222212339 [doi]
LID - 12339
AB  - Dendritic cells (DCs) are immune specialized cells playing a critical role in 
      promoting immune response against antigens, and may represent important targets 
      for therapeutic interventions in cancer. DCs can be stimulated ex vivo with 
      pro-inflammatory molecules and loaded with tumor-specific antigen(s). Protocols 
      describing the specific details of DCs vaccination manufacturing vary widely, but 
      regardless of the employed protocol, the DCs vaccination safety and its ability 
      to induce antitumor responses is clearly established. Many years of studies have 
      focused on the ability of DCs to provide overall survival benefits at least for a 
      selection of cancer patients. Lessons learned from early trials lead to the 
      hypothesis that, to improve the efficacy of DCs-based immunotherapy, this should 
      be combined with other treatments. Thus, the vaccine's ultimate role may lie in 
      the combinatorial approaches of DCs-based immunotherapy with chemotherapy and 
      radiotherapy, more than in monotherapy. In this review, we address some key 
      questions regarding the integration of DCs vaccination with multimodality therapy 
      approaches for cancer treatment paradigms.
FAU - Nava, Sara
AU  - Nava S
AUID- ORCID: 0000-0001-9912-8255
AD  - Cell Therapy Production Unit, Neurology Unit, UCV, Neurological Institute "C. 
      Besta" IRCCS Foundation, Via Celoria 11, 20133 Milan, Italy.
FAU - Lisini, Daniela
AU  - Lisini D
AUID- ORCID: 0000-0002-7436-8401
AD  - Cell Therapy Production Unit, Neurology Unit, UCV, Neurological Institute "C. 
      Besta" IRCCS Foundation, Via Celoria 11, 20133 Milan, Italy.
FAU - Frigerio, Simona
AU  - Frigerio S
AUID- ORCID: 0000-0001-7078-075X
AD  - Cell Therapy Production Unit, Neurology Unit, UCV, Neurological Institute "C. 
      Besta" IRCCS Foundation, Via Celoria 11, 20133 Milan, Italy.
FAU - Bersano, Anna
AU  - Bersano A
AUID- ORCID: 0000-0002-2493-628X
AD  - Cell Therapy Production Unit, Neurology Unit, UCV, Neurological Institute "C. 
      Besta" IRCCS Foundation, Via Celoria 11, 20133 Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211115
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Combined Modality Therapy/methods
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/*drug therapy/immunology/*radiotherapy
MH  - Progression-Free Survival
MH  - Tumor Escape/drug effects/radiation effects
PMC - PMC8620771
OTO - NOTNLM
OT  - adjuvant therapy
OT  - cancer
OT  - dendritic cells
OT  - immunotherapy
COIS- The authors declare no conflict of interest.
EDAT- 2021/11/28 06:00
MHDA- 2021/12/21 06:00
PMCR- 2021/11/15
CRDT- 2021/11/27 01:11
PHST- 2021/09/29 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/11/12 00:00 [accepted]
PHST- 2021/11/27 01:11 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/12/21 06:00 [medline]
PHST- 2021/11/15 00:00 [pmc-release]
AID - ijms222212339 [pii]
AID - ijms-22-12339 [pii]
AID - 10.3390/ijms222212339 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Nov 15;22(22):12339. doi: 10.3390/ijms222212339.